Effect of Linagliptin and Empagliflozine on diabetes
Phase 2
Recruiting
- Conditions
- Diabetes type 2.Type 2 diabetes mellitus
- Registration Number
- IRCT20221016056201N1
- Lead Sponsor
- Arak University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 55
Inclusion Criteria
patients who have been diagnosed with type 2 diabetes mellitus based on the ADA diagnostic criteria and indicated for medical therapy
patients who have not reached to treatment goals despite receiving previous medications
Exclusion Criteria
type 1 diabetes
pregnancy
diabetic ketoacidosis (present and previous)
pancreatitis (present and previous)
diabetic foot ulcer (present and previous)
GFR less than 30
BMI less than 18.5
severe adverse drug reactions
lack of consent to participate in the study
untreated urinary tract infection
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Fasting blood sugar. Timepoint: beginning of the study, 3 months later. Method of measurement: blood sample.
- Secondary Outcome Measures
Name Time Method Glycosylated hemoglobin. Timepoint: beginning of the study, 3 months later. Method of measurement: blood sample.